About: Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools
Creator	Lv, Qi Gu, Yu Wu, Yue Chen, Xiuping Gong, Shuran Qi, Feifei Kong, Qi
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: Pudilan (PDL), a four-herb prescription with the traditional function of heat-clearing and detoxifying, has been clinically used as an anti-SARS-CoV-2 infectory agent in China for decades. PDL might also have therapeutic potentials for COVID-19 while the underlying mechanisms remain to be clarified. METHODS: We used network pharmacology analysis and selected 68 co-targeted genes/proteins as targets of both PDL and COVID-19. These co-targeted genes/proteins were predicted by SwissDock Server for their high-precision docking simulation, and analyzed by STRING for proteins to protein interaction (PPI), pathway and GO (gene ontology) enrichment. The therapeutic effect for PDL treatment on COVID-19 was validated by the TCMATCOV (TCM Anti COVID-19) platform. RESULTS: PDL might prevent the entrance of SARS-CoV-2 entry into cells by blocking the angiotensin-converting enzyme 2 (ACE2). It might inhibit the cytokine storm by affecting C-reactive protein (CRP), interferon-γ (IFN-γ), interleukin- 6 (IL-6), interleukin- 10 (IL-10), tumor necrosis factor (TNF), epidermal growth factor receptor (EGFR), C-C motif chemokine ligand 5 (CCL5), transforming growth factor-β1 (TGFβ1), and other proteins. PDL might moderate the immune system to shorten the course of the disease, delay disease progression, and reduce the mortality rate. CONCLUSION: PDL might have a therapeutic effect on COVID-19 through three aspects, including the moderate immune system, anti-inflammation, and anti-virus entry into cells.
has issue date	2020-05-30(xsd:dateTime)
bibo:doi	10.1016/j.biopha.2020.110316
bibo:pmid	32505821
has license	no-cc
sha1sum (hex)	d14d114d813c5a5508db1b81da6471ca3401cdca
schema:url	https://doi.org/10.1016/j.biopha.2020.110316
resource representing a document's title	Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools
has PubMed Central identifier	PMC7260557
has PubMed identifier	32505821
schema:publication	Biomed Pharmacother
resource representing a document's body	covid:d14d114d813c5a5508db1b81da6471ca3401cdca#body_text
is schema:about of	named entity 'proven' named entity 'disease' named entity 'cytokine storm' named entity 'molecular' named entity 'mechanism' named entity '2019' named entity 'PDL' named entity 'mechanism' named entity 'COVID-19' named entity 'Interleukin-1β' named entity 'proteins' named entity 'coronavirus disease' named entity 'molecular mechanism' named entity 'pharmacology' named entity 'COVID-19' named entity 'COVID-19' named entity 'Reactome' named entity 'molecular mechanism' named entity 'COVID-19' named entity 'CRP' named entity 'NF-κB' named entity 'molecular mechanism' named entity 'synapse' named entity 'COVID' named entity 'IL-6' named entity 'toll-like receptor 4' named entity 'Reactome' named entity 'immune response' named entity 'Vero cells' named entity 'China' named entity 'cough' named entity 'COVID' named entity 'mice' named entity 'biological processes' named entity 'TNF-α' named entity 'anti-inflammatory' named entity 'Baicalin' named entity 'COVID' named entity 'inflammatory mediators' named entity 'Shen Fu' named entity 'infection' named entity 'infection' named entity 'CD147' named entity 'pharmacology' named entity 'receptor' named entity 'serum' named entity 'IL-6' named entity 'Bioinformatics' named entity 'Traditional Chinese Medicine' named entity 'mRNA' named entity 'Reactome' named entity 'obstructive airway disease' named entity 'SARS-CoV-2' named entity 'Clinical practice' named entity 'IL-6' named entity 'human cytomegalovirus' named entity 'TCM' named entity 'COVID-19 disease' named entity 'TNF-α' named entity 'COVID-19' named entity 'COVID-19' named entity 'CCL5' named entity 'IL-6' named entity 'TLR4' named entity 'IL-8' named entity 'SARS-CoV-2' named entity 'protein' named entity 'type I interferons' named entity 'asthma' named entity 'COVID-19' named entity 'COVID' named entity 'anti-inflammation' named entity 'NF-κB' named entity 'IL-6' named entity 'statistically significant'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software